2023
Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
Minta A, Rose L, Park C, Ramaswamy B, Stover D, Gatti-Mays M, Cherian M, Williams N, Sudheendra P, Wesolowski R, Sardesai S, Lustberg M, Loprinzi C, Ruddy K, Cathcart-Rake E, Trovato S, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients. Supportive Care In Cancer 2023, 31: 717. PMID: 37991653, DOI: 10.1007/s00520-023-08160-0.Peer-Reviewed Original ResearchConceptsBreast cancer patientsTherapeutic responseAdverse eventsClinical characteristicsCancer patientsCommon cutaneous adverse eventsCutaneous adverse eventsPoor systemic absorptionRetrospective cohort studyComparison of pretreatmentEIA patientsEndocrine monotherapyClinical improvementCohort studyRetrospective cohortOncologic treatmentTopical antiandrogenCombination therapySystemic absorptionAndrogenetic alopeciaDean scaleMethodsThis studyPatientsAlopeciaScore grade
2022
Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management
Pach J, Leventhal J. Cutaneous Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors and Their Management. Critical Reviews In Immunology 2022, 42: 1-20. PMID: 37022356, DOI: 10.1615/critrevimmunol.2023046895.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsCheckpoint inhibitorsT cellsAdverse eventsCutaneous immune-related adverse eventsImmune checkpoint inhibitor therapyInhibition of T cellsOveractivation of T cellsCheckpoint inhibitor therapyImmune checkpoint inhibitorsCutaneous adverse eventsStevens-Johnson syndromeCutaneous autoimmune diseasesToxic epidermal necrolysisPre-existing diseaseLife-threatening eruptionsInhibitor therapyTreatment interruptionImmune dysregulationImmune surveillanceMaculopapular eruptionEpidermal necrolysisAutoimmune diseasesBullous dermatosisAntitumor activity
2021
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.
Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. Journal Of Drugs In Dermatology 2021, 20: 3ss-s19. PMID: 34491030, DOI: 10.36849/jdd.6229.Peer-Reviewed Original ResearchConceptsCutaneous adverse eventsCancer patientsAnticancer treatmentEvidence-based algorithmNumber of patientsQuality of studiesAdverse eventsOncology patientsPatients' qualityPatient outcomesSun protection productsSurvivors' qualitySkincare regimenCounter agentsSkin conditionsPatientsHealthcare providersHealthy skinMultidisciplinary teamCancer treatmentAdvanced providersGeneral measuresTreatmentDelphi approachSkincare formulationsErythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event
Pach J, Moody K, Ring N, Panse G, Zhang M, Deverapalli S, Leventhal J. Erythema nodosum-like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event. JAAD Case Reports 2021, 13: 118-120. PMID: 34189226, PMCID: PMC8220292, DOI: 10.1016/j.jdcr.2021.05.002.Peer-Reviewed Original Research
2020
Cutaneous immune-related adverse events to checkpoint inhibitors
Malviya N, Tattersall IW, Leventhal J, Alloo A. Cutaneous immune-related adverse events to checkpoint inhibitors. Clinics In Dermatology 2020, 38: 660-678. PMID: 33341200, DOI: 10.1016/j.clindermatol.2020.06.011.Peer-Reviewed Original ResearchConceptsAdverse reactionsCheckpoint inhibitorsImmune-related adverse reactionsCheckpoint inhibitor therapyCutaneous adverse eventsOngoing cancer treatmentPD-1 inhibitorsCTLA-4 inhibitorsImmune checkpoint inhibitorsCutaneous adverse reactionsPD-L1 inhibitorsDevelopment of immunotherapySuch adverse reactionsImmunomodulatory therapyTreatment interruptionAssociated morbidityPatient comorbiditiesAdverse eventsCutaneous toxicityInhibitor therapyImmune statusHematologic malignanciesEarly recognitionCancer treatmentManagement guidelinesCommunity Private Practice Clinical Experience with Peanut Oral Immunotherapy
Afinogenova Y, Rubin T, Patel S, Powell R, Gilo J, Denno M, Soffer G, Lee J, Mendelson L, Factor J. Community Private Practice Clinical Experience with Peanut Oral Immunotherapy. The Journal Of Allergy And Clinical Immunology In Practice 2020, 8: 2727-2735. PMID: 32247684, DOI: 10.1016/j.jaip.2020.03.016.Peer-Reviewed Original ResearchConceptsPeanut oral immunotherapyPeanut-specific IgE levelsCutaneous adverse eventsRespiratory adverse eventsGastrointestinal adverse eventsAdverse eventsSpecific IgE levelsPeanut-allergic patientsOral immunotherapySystemic reactionsIgE levelsAdverse reactionsRetrospective chart reviewSpecific patient characteristicsMaintenance phaseAllergic profileGastrointestinal symptomsChart reviewImmunologic factorsPatient characteristicsPatient demographicsBlood pressureEosinophilic esophagitisAllergy testingPeanut allergy
2009
Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab.
Hickish T, Wheatley D, Lin N, Carey L, Houston S, Mendelson D, Solca F, Uttenreuther-Fischer M, Jones H, Winer E. Use of BIBW 2992, a Novel Irreversible EGFR/HER1 and HER2 Tyrosine Kinase Inhibitor To Treat Patients with HER2-Positive Metastatic Breast Cancer after Failure of Treatment with Trastuzumab. Cancer Research 2009, 69: 5060-5060. DOI: 10.1158/0008-5472.sabcs-09-5060.Peer-Reviewed Original ResearchHER2-positive metastatic breast cancerEpidermal growth factor receptorPhase II studyMetastatic breast cancerBIBW 2992Partial responseBreast cancerGrowth factor receptorII studyEastern Cooperative Oncology Group performance statusSingle-arm phase II studyHER2-positive breast cancer patientsTrastuzumab-resistant cell linesHER2-positive breast cancerHER2 tyrosine kinase inhibitorAdequate organ functionCutaneous adverse eventsEarly clinical responseObjective response rateFactor receptorBreast cancer patientsFailure of treatmentTyrosine kinase inhibitorsEligible patientsMeasurable disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply